{"entity":{"id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","aka":[],"tldr":"A phase 2 trial of paclitaxel / nab-paclitaxel, carboplatin and pembrolizumab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, not yet recruiting.","summary":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial is a phase 2, interventional study registered as NCT07610525 by M.D. Anderson Cancer Center, with a registry enrolment figure of 200 participants, started 2026-11-05 and due to reach its primary completion in 2029-01-15. Interventions recorded: Paclitaxel + Carboplatin; Pembrolizumab. Conditions listed: Triple Negative Breast Cancer; Blood and Image Guided; Optimization of Neoadjuvant Therapy; Phase 2. Triple-negative eligibility wording from the registry: \"* Histologically proven TNBC, defined as ER ≤10%, PR ≤10%, and HER2 negative based on the 2023 ASCO/CAP guidelines\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07610525","url":"https://clinicaltrials.gov/study/NCT07610525"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["paclitaxel","carboplatin","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07610525","phase":"2","setting":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Tria","sponsor":"M.D. Anderson Cancer Center","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07610525/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}